The present invention relates generally to the treatment of end stage renal disease. More specifically, the present invention relates to methods and apparatus for monitoring the performance of peritoneal dialysis.
Using dialysis to support a patient whose renal function has decreased to the point where the kidneys no longer sufficiently function is known. Two principal dialysis methods are utilized: hemodialysis; and peritoneal dialysis.
In hemodialysis, the patient's blood is passed through an artificial kidney dialysis machine. A membrane in the machine acts as an artificial kidney for cleansing the blood. Because it is an extracorporeal treatment that requires special machinery, certain inherent disadvantages exist with hemodialysis.
To overcome the disadvantages associated with hemodialysis, peritoneal dialysis was developed. Peritoneal dialysis utilizes the patient's own peritoneum as a semi-permeable membrane. The peritoneum is a membranous lining of the abdominal body cavity. Due to good perfusion, the peritoneum is capable of acting as a natural semi-permeable membrane.
Peritoneal dialysis periodically infuses sterile aqueous solution into the peritoneal cavity. This solution is called peritoneal dialysis solution, or dialysate. Diffusion and osmosis exchanges take place between the solution and the blood stream across the natural body membranes. These exchanges remove the waste products that the kidneys normally excrete. The waste products typically consist of solutes like urea and creatinine. The kidneys also maintain the levels of other substances such as sodium and water which need to be regulated by dialysis. The diffusion of water and solutes across the peritoneal membrane during dialysis is called ultrafiltration.
In continuous ambulatory peritoneal dialysis, a dialysis solution is introduced into the peritoneal cavity utilizing a catheter. An exchange of solutes between the dialysate and the blood is achieved by diffusion. Further removal is achieved by providing a suitable osmotic gradient from the blood to the dialysate to permit water outflow from the blood. This allows a proper acid-base, electrolyte and fluid balance to be achieved in the body. The dialysis solution is simply drained from the body cavity through the catheter.
Peritoneal dialysis raises a number of concerns including: the danger of peritonitis; a lower efficiency and therefore increased duration of dialysis hours compared to hemodialysis; and costs incurred when automated equipment is utilized.
A number of variations on peritoneal dialysis have been explored. One such variation is automated peritoneal dialysis (“APD”). APD uses a machine, called a cycler, to automatically infuse, dwell, and drain peritoneal dialysis solution to and from the patient's peritoneal cavity. APD is particularly attractive to a peritoneal dialysis patient, because it can be performed at night while the patient is asleep. This frees the patient from the day-to-day demands of continuous ambulatory peritoneal dialysis during his/her waking and working hours.
The APD sequence typically lasts for several hours. It often begins with an initial drain cycle to empty the peritoneal cavity of spent dialysate. The APD sequence then proceeds through a succession of fill, dwell, and drain phases that follow one after the other. Each fill/dwell/drain sequence is called a cycle. APD can be and is practiced in a number of different ways.
Current APD systems do not monitor the patient intraperitoneal pressure during a therapy session. Current systems simply limit the external pressure (or suction) that a pump can apply to the line or lumen that is attached to the patient catheter. If the patient is located below the system, sometimes referred to as a cycler, a gravity head will add to the positive fill pressure that the cycler can apply to the patient catheter. Conversely, if the patient is located above the cycler, the gravity head will decrease from the positive fill pressure that the cycler can apply to the patient catheter.
The monitoring of intraperitoneal pressure would be useful because cyclers will sometimes not fully drain a patient between cycles. Specifically, currently-available cyclers are unable to determine whether a patient absorbed some fluid or whether some fluid is simply not able to be drained out because of the position of the patient or the catheter.
As a result, some currently-available systems utilize a minimum drain threshold to determine the amount of fluid that should be delivered to the patient during the next fill. For example, if 85% of the fill volume has been drained when the cycler determines that the patient is “empty”, the next fill volume will be 100%. If only 80% were drained, the next fill volume would be limited to 95%.
A negative ultrafiltrate (uF) alarm will sound when the patient has retained more than a predetermined percentage of the fill volume. The predetermined percentage can typically be either 50% or 100% of the fill volume. However, the patient can override this alarm if he/she does not feel overfull. The number of times the patients can override the uF alarm during a single therapy may be limited by the software of the cycler. However, the uF alarm typically does not consider the actual ultrafiltrate that may also accumulate in the peritoneal cavity along with the dialysate.
Currently-available cyclers fill the patient to a specific, preprogrammed volume during each cycle. The doctor prescribes this fill volume based upon the patient's size, weight and other factors. However, because currently-available cyclers cannot monitor intraperitoneal pressure, the doctor cannot take this factor into account when formulating the prescription. It is also known that intraperitoneal pressure (IPP) has an effect on ultrafiltration (UF).
Referring to
Turning to
Turning to
The drain and fill rates of the cyclers 10a-10c illustrated in
Accordingly, there is a need for an improved cycler that measures patient intraperitoneal pressure during a therapy session, including both during the drain and the fill as well as the dwell. Further, there is a need for an improved cycler that measures intraperitoneal pressure and which would use that data to more completely drain a patient between cycles. Further, there is a need for an improved cycler which would accurately measure intraperitoneal pressure to avoid overfilling a patient. Finally, there is a need for an improved cycler which would monitor intraperitoneal pressure during both the fill and drain cycles to optimize the speed at which the patient is filled and drained and to therefore increase the dwell portion of a therapy session.
The present invention satisfies the aforenoted needs by providing a system for providing peritoneal dialysis to a patient which comprises a dialysate container connected to the patient with a first pressure sensor connected in-line therebetween, and a drain container connected to the patient with a second pressure sensor connected in-line therebetween.
In an embodiment, the system further comprises a first pump disposed in-line between the dialysate container and the first pressure sensor.
In an embodiment, the dialysate flows from the dialysate container into the patient under a hydrostatic head.
In an embodiment, a second pump is disposed in-line between the drain container and the second pressure sensor.
In an embodiment, the dialysate flows from the patient to the drain container under a hydrostatic head.
In an embodiment, the second pressure sensor measures an intraperitoneal pressure of the patient while dialysate flows from the dialysate container to the patient.
In an embodiment, the first pressure sensor measures an intraperitoneal pressure of the patient while dialysate flows from the patient to the drain container.
In an embodiment, the system further comprises a first lumen connecting the dialysate container to the first sensor and the first sensor to a catheter, and a second lumen connecting the drain container to the second sensor and the second sensor to the catheter, the catheter being connected to the patient, a flow of dialysate from the patient to the drain container evacuating dialysate from the first lumen and causing said dialysate from the first lumen to flow through the second lumen and to the drain container.
In an embodiment, the catheter is a dual lumen catheter.
In an embodiment, the first and second sensors are redundant in-line pressure/vacuum sensors.
In an embodiment, the present invention provides a method for dialyzing a patient comprising the steps of: placing a catheter in a peritoneum of the patient; providing at least one dialysate container; connecting the dialysate container to the catheter with a first lumen that includes a first pressure sensor disposed in-line and between the catheter and the dialysate container; providing at least one drain container; connecting the drain container to the catheter with a second lumen that includes a second pressure sensor disposed in-line and between the catheter and the drain container; transferring dialysate from the dialysate container to the peritoneum of the patient and monitoring an intraperitoneal pressure of the patient with the second pressure sensor; and transferring dialysate from the peritoneum of the patient to the drain container and monitoring the intraperitoneal pressure of the patient with the first pressure sensor.
In an embodiment, the step of transferring dialysate from the dialysate container to the peritoneum of the patient further comprises pumping dialysate from the dialysate container to the patient with a first pump disposed in-line between the dialysate container and the first pressure sensor.
In an embodiment, the step of transferring dialysate from the peritoneum of the patient to the drain container further comprises pumping dialysate from the peritoneum of the patient to the drain container with a second pump disposed in-line between the drain container and the second pressure sensor.
In an embodiment, the dialysate container is disposed vertically above the peritoneum of the patient and the step of transferring dialysate from the dialysate container to the peritoneum of the patient further comprises flowing dialysate from the dialysate container to the patient under a hydrostatic head.
In an embodiment, the drain container is disposed vertically below the peritoneum of the patient and the step of transferring dialysate from the peritoneum of the patient to the drain container further comprises flowing dialysate from the peritoneum of the patient to the drain container under a hydrostatic head.
Other objects and advantages of the invention will become apparent upon reading the following detailed description and appended claims, and upon reference to the accompanying drawings.
It should be understood that the drawings are not necessarily to scale and that the embodiments are sometimes illustrated by graphic symbols, phantom lines, diagrammatic representations and fragmentary views. In certain instances, details which are not necessary for an understanding of the present invention or which render other details difficult to perceive may have been omitted. It should be understood, of course, that the invention is not necessarily limited to the particular embodiments illustrated herein.
Turning to
During the drain, the sensor 32 can accurately monitor and measure the intraperitoneal pressure of the patient 12. In the embodiment illustrated in
Turning to
Turning to
In the embodiment 70 illustrated in
When the left diaphragm pump 126 is pushing dialysate to the patient, the sensor 123 can measure the intraperitoneal pressure through the line 89. When the left diaphragm pump 126 is draining fluid from the patient through the line 89, the sensor 120 can measure intraperitoneal pressure through the line 88 and while the right pump 127 is pumping fluid to the drain container (not shown) through the drain line shown schematically at 128. When the right diaphragm pump 127 is being used to drain fluid from the patient, the sensor 120 can measure intraperitoneal pressure while the left diaphragm pump 126 is pumping fluid to the drain container (not shown) through the drain line shown schematically at 129.
A comparison of an APD therapy for a prior art APD cyclers and one manufactured in accordance with the present invention are summarized as follows:
Inspection of Table 1 shows that cycler 1 woke the patient at around 4:30 in the morning with a negative uF alarm at the beginning of Fill 5. The patient bypassed the alarm because he did not feel overfull and immediately fell back asleep. He woke up about 15 minutes later when he had difficulty breathing and felt extremely overfull. He manually drained about 1500 ml but was unable to go back to sleep. He filed a formal product complaint with the manufacturer.
The data of Table 1 shows that cycler 2 ran a completely normal therapy but the total therapy clearance (calculated based upon the sum of the night patient volumes) was only 84.5% of that obtained by cycler 3, which was using the cycler that used the method of the current invention.
The data of Table 1 shows that cycler 3 ran a completely normal therapy and that the fill volume was limited on one occasion by the maximum fill volume but on four occasions by the patient's intraperitoneal pressure. This patient never felt any discomfort and had no alarms during the night. The limit on the IPP prevented him from being overfilled even though he had successive drains that were not complete. The volume of fluid in his peritoneum never exceeded 3 liters.
The patient on cycler 1 had an intraperitoneal pressure in excess of 14 mm Hg during dwells 3 and 4. His breathing may have been impaired and his heart may have had to work harder but the discomfort was not enough to wake him up from a sound sleep until it peaked at 4,099 ml during dwell 5.
In conclusion, the method of the present invention provides for optimum fills and therefore more clearance while preventing overfills that bring discomfort and inhibit the function of vital body organs. A negative uF alarm would seldom occur because overfills of the required magnitude would be prevented by the IPP sensors.
In order to calculate the IPP, one may first calculate the patient head height correction using conservation of energy:
Δ(1/2ρV2+P−ρagh)+Frictional Losses=0
The velocity V of fluid through the patient line is the same at both ends of the line as is the fluid density, so this equation can be written as
(P2−P1)−ρag(h2−h1)+Frictional Losses=0
which can be rearranged as
Turning to
It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the present invention and without diminishing its attendant advantages. It is, therefore, intended that such changes and modifications be covered by the appended claims.
This application is a divisional application of U.S. patent application Ser. No. 10/078,568, filed Feb. 14, 2002, entitled, “Method and Apparatus for Monitoring and Controlling Peritoneal Dialysis Therapy,” issued as U.S. Pat. No. 6,592,542, which is a continuation of U.S. patent application Ser. No. 09/501,778, filed Feb. 10, 2000, having the same title as above, issued as U.S. Pat. No. 6,497,676. Both disclosures are hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3620215 | Tysk et al. | Nov 1971 | A |
3707967 | Kitrilakis et al. | Jan 1973 | A |
4096859 | Agarwal et al. | Jun 1978 | A |
4184497 | Kolff et al. | Jan 1980 | A |
4239041 | Popovich et al. | Dec 1980 | A |
4240408 | Schael | Dec 1980 | A |
4306976 | Bazzato | Dec 1981 | A |
4316466 | Babb | Feb 1982 | A |
4338190 | Kraus et al. | Jul 1982 | A |
4351333 | Lazarus et al. | Sep 1982 | A |
4368737 | Ash | Jan 1983 | A |
4381003 | Buoncristiani | Apr 1983 | A |
4396382 | Goldhaber | Aug 1983 | A |
4398910 | Blake et al. | Aug 1983 | A |
4412917 | Ahjopalo | Nov 1983 | A |
D272651 | Mahurkar | Feb 1984 | S |
4464172 | Lichtenstein | Aug 1984 | A |
4465481 | Blake | Aug 1984 | A |
4490137 | Moukheibir | Dec 1984 | A |
4496349 | Cosentino | Jan 1985 | A |
4498902 | Ash et al. | Feb 1985 | A |
4543087 | Sommercorn et al. | Sep 1985 | A |
4560472 | Granzow et al. | Dec 1985 | A |
4581012 | Brown et al. | Apr 1986 | A |
4585436 | Davis et al. | Apr 1986 | A |
4586920 | Peabody | May 1986 | A |
4618343 | Polaschegg | Oct 1986 | A |
4681564 | Landreneau | Jul 1987 | A |
4687471 | Twardowski et al. | Aug 1987 | A |
4704102 | Guthery | Nov 1987 | A |
4747822 | Peabody | May 1988 | A |
4772269 | Twardowski et al. | Sep 1988 | A |
4832054 | Bark | May 1989 | A |
4842582 | Mahurkar | Jun 1989 | A |
4895561 | Mahurkar | Jan 1990 | A |
4935004 | Cruz | Jun 1990 | A |
5004459 | Peabody et al. | Apr 1991 | A |
5037385 | O'Byrne | Aug 1991 | A |
5053023 | Martin | Oct 1991 | A |
5057073 | Martin | Oct 1991 | A |
5057075 | Moncrief et al. | Oct 1991 | A |
5098413 | Trudell et al. | Mar 1992 | A |
5106368 | Uldall et al. | Apr 1992 | A |
5120303 | Hombrouckx | Jun 1992 | A |
5141493 | Jacobsen et al. | Aug 1992 | A |
5188593 | Martin | Feb 1993 | A |
5197951 | Mahurkar | Mar 1993 | A |
5207650 | Martin | May 1993 | A |
5209723 | Twardowski et al. | May 1993 | A |
5221255 | Mahurkar et al. | Jun 1993 | A |
5221256 | Mahurkar | Jun 1993 | A |
5250041 | Folden et al. | Oct 1993 | A |
5254084 | Geary | Oct 1993 | A |
5277820 | Ash | Jan 1994 | A |
5322519 | Ash | Jun 1994 | A |
5334139 | Jeppsson et al. | Aug 1994 | A |
5336173 | Folden | Aug 1994 | A |
5338293 | Jeppsson et al. | Aug 1994 | A |
5346471 | Raulerson | Sep 1994 | A |
5350358 | Martin | Sep 1994 | A |
5364344 | Beattie et al. | Nov 1994 | A |
5378230 | Mahurkar | Jan 1995 | A |
5380276 | Miller et al. | Jan 1995 | A |
5421814 | Geary | Jun 1995 | A |
5423768 | Folden et al. | Jun 1995 | A |
5464398 | Haindl | Nov 1995 | A |
5498338 | Kruger et al. | Mar 1996 | A |
5527274 | Zakko | Jun 1996 | A |
5542919 | Simon et al. | Aug 1996 | A |
5569182 | Twardowski et al. | Oct 1996 | A |
5628908 | Kamen et al. | May 1997 | A |
5634896 | Bryant et al. | Jun 1997 | A |
5641405 | Keshaviah et al. | Jun 1997 | A |
5643201 | Peabody et al. | Jul 1997 | A |
5685867 | Twardowski et al. | Nov 1997 | A |
5718692 | Schon et al. | Feb 1998 | A |
5722947 | Jeppsson et al. | Mar 1998 | A |
5776111 | Tesio | Jul 1998 | A |
5788680 | Linder | Aug 1998 | A |
5795326 | Simán | Aug 1998 | A |
5807311 | Palestrant | Sep 1998 | A |
5931829 | Burbank et al. | Aug 1999 | A |
5938634 | Packard | Aug 1999 | A |
5947953 | Ash et al. | Sep 1999 | A |
5961486 | Twardowski et al. | Oct 1999 | A |
5964796 | Imran | Oct 1999 | A |
5968009 | Simán | Oct 1999 | A |
5976103 | Martin | Nov 1999 | A |
5989206 | Prosl et al. | Nov 1999 | A |
6001078 | Reekers | Dec 1999 | A |
6001079 | Pourchez | Dec 1999 | A |
6048329 | Thompson et al. | Apr 2000 | A |
6074359 | Keshaviah et al. | Jun 2000 | A |
6074374 | Fulton | Jun 2000 | A |
6117106 | Wasicek et al. | Sep 2000 | A |
6126631 | Loggie | Oct 2000 | A |
6132405 | Nilsson et al. | Oct 2000 | A |
6146354 | Beil | Nov 2000 | A |
6156016 | Maginot | Dec 2000 | A |
6159195 | Ha et al. | Dec 2000 | A |
6190349 | Ash et al. | Feb 2001 | B1 |
6190371 | Maginot et al. | Feb 2001 | B1 |
6193684 | Burbank et al. | Feb 2001 | B1 |
6206849 | Martin et al. | Mar 2001 | B1 |
6228047 | Dadson | May 2001 | B1 |
6234991 | Gorsuch | May 2001 | B1 |
6245039 | Brugger et al. | Jun 2001 | B1 |
6248092 | Miraki et al. | Jun 2001 | B1 |
6254567 | Treu et al. | Jul 2001 | B1 |
6258079 | Burbank et al. | Jul 2001 | B1 |
6280423 | Davey et al. | Aug 2001 | B1 |
6290669 | Zicherman | Sep 2001 | B1 |
6302875 | Makower et al. | Oct 2001 | B1 |
6409699 | Ash | Jun 2002 | B1 |
6491658 | Miura et al. | Dec 2002 | B1 |
6558340 | Traeger | May 2003 | B1 |
6561996 | Gorsuch | May 2003 | B1 |
6561997 | Funke et al. | May 2003 | B1 |
6585682 | Haraldsson et al. | Jul 2003 | B1 |
6666842 | Sakai | Dec 2003 | B1 |
7004924 | Brugger et al. | Feb 2006 | B1 |
20010014793 | Brugger et al. | Aug 2001 | A1 |
20030220600 | Gotch et al. | Nov 2003 | A1 |
Number | Date | Country |
---|---|---|
3522782 | Jan 1987 | DE |
3739556 | Jun 1989 | DE |
0 333 308 | Sep 1989 | EP |
0 381 042 | Aug 1990 | EP |
0 504 934 | Sep 1992 | EP |
0 535 874 | Apr 1993 | EP |
0 554 722 | Aug 1993 | EP |
0 684 845 | Dec 1995 | EP |
1 110 564 | Jun 2001 | EP |
1 110 565 | Jun 2001 | EP |
2245 496 | Jan 1992 | GB |
WO 8803389 | May 1988 | WO |
WO 9535124 | Dec 1995 | WO |
WO 9817333 | Apr 1998 | WO |
WO 9850088 | Nov 1998 | WO |
WO 9907301 | Feb 1999 | WO |
WO 9906082 | Nov 1999 | WO |
WO 0010385 | Mar 2000 | WO |
WO 0020050 | Apr 2000 | WO |
WO 0158509 | Aug 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20030204162 A1 | Oct 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10078568 | Feb 2002 | US |
Child | 10446068 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09501778 | Feb 2000 | US |
Child | 10078568 | US |